September Series

Tuesday, September 7, 2021

Studylog
10:00 AM - 10:20 AM
Animal Study Workflow Software: A Solution to Problems of Reproducibility
Eric Ibsen, Studylog Systems, Inc., San Francisco, California

Reaction Biology
10:20 AM - 10:40 AM
SubQperiorTM: An innovative and superior syngeneic model system
Holger Weber, Reaction Biology, Freiburg, Germany

Miltenyi Biotec
10:40 AM - 11:00 AM
Early identification of target candidates for pancreatic adenocarcinoma immunotherapy
Daniel Schäfer, R&D Miltenyi Biotec, Bergisch Gladbach, Germany

FujiFilm VisualSonics, Inc.
11:00 AM - 11:20 AM
Seeing Cancer in a New Light: Ultrasound and Photoacoustics for Tumor Imaging
Lindsey Hughes, FujiFilm VisualSonics, Inc., Toronto, Ontario
Sarah Burris, FujiFilm VisualSonics, Inc., Toronto, Ontario

Agilent Technologies
11:20 AM - 11:40 AM
Streamline your NGS workflow for Cancer Research
Brigette Brown Kipphut, Agilent Technologies, Santa Clara, California

BREAK
11:40 AM – 1:00 PM

BioLegend
1:00 PM – 1:20 PM
See 3D (Ce3D™): Enhanced Tissue Clearing for Multicolor Microscopy
Anna Cartier, BioLegend, San Diego, California

BREAK
1:20 PM – 2:00 PM

GeneCopoeia
2:00 PM – 2:20 PM
Strategies for Effective Gene Modification Using CRISPR Products from GeneCopoeia
Ed Davis, GeneCopoeia, Rockville, Maryland
September Series

Thursday, September 9, 2021

vivoPharm
10:00 AM - 10:20 AM
Discovery Services for Oncology & Toxicology
Roland Carrillo, vivoPharm, Hershey, Pennsylvania

ROKIT Healthcare
10:20 AM - 10:40 AM
Bioprinting in Tumor Biology: Recent Trends in 3D Tumor Microenvironment Modeling
Da-Yae Lee, ROKIT Healthcare, Geumcheon-gu, Seoul, Korea

Luminex Corporation
10:40 AM - 11:00 AM
Multiplex Immunoassays for Profiling Plasma Cytokines in Brain Tumor Subjects
Diane Bender, Washington University of St. Louis, St. Louis, Missouri

NeoGenomics Laboratories
11:00 AM - 11:20 AM
Comprehensive analysis of immuno oncology markers in the Tumor microenvironment of solid tumor samples using GeoMxTM Digital Spatial Profiler (DSP) and MultiOmyxTM Hyperplexed Immunofluorescence (IF)
Lakshmi Chandramohan, NeoGenomics, Houston, Texas

Oxford Nanopore Technologies Ltd.
11:20 AM – 11:40 AM
Intraoperative DNA methylation classification of brain tumors impacts neurosurgical
Luna Djirackor, Oslo University Hospital, Oslo, Norway

BREAK
11:40 AM – 1:00 PM

EpiCypher
1:00 PM – 1:20 PM
Leveraging epigenomics to accelerate chromatin research and drug discovery
Andrea Johnstone, EpiCypher, Durham, North Carolina

BREAK
1:20 PM – 2:00 PM

QIAGEN
2:00 PM – 2:20 PM
Standardizing cell-free DNA sample processing – A true walkaway solution for automated cfDNA isolation from up to 8 ml
Constanze Kindler, QIAGEN, Hilden, Germany
**September Series**

**Tuesday, September 21, 2021**

**Philips Molecular Pathway Diagnostics**
10:00 AM - 10:20 AM  
Measurement of activity of signal transduction pathways in individual patient tissue and blood samples to quantify innate and adaptive immune response and predict response to immunotherapy  
Anja van de Stolpe, Philips Molecular Pathway Diagnostics, Eindhoven, The Netherlands

**Promega Corporation**
10:20 AM - 10:40 AM  
Improved DAMP Assays for Accelerating Immuno-Oncology Drug Discovery  
Andrew Niles, Promega Corporation, Madison, Wisconsin

**Envigo**
10:40 AM - 11:00 AM  
Development and characterization of the ultra-immunodeficient B-NDG mouse model  
Travis Rothrock, Envigo, Indianapolis, Indiana

**CELLINK**
11:00 AM - 11:20 AM  
How to get more from your cell-based assays: Automated live-cell analysis with the CELLCYTE X  
Silvano Paternoster, CYTENA, Gothenburg, Sweden

**Indica Labs**
11:20 AM – 11:40 AM  
Identifying high risk colorectal cancer patients through Indica Labs’ HALO® software  
Peter Caie, Indica Labs, Albuquerque, New Mexico

**Bionano Genomics**
11:40 AM – 12:00 PM  
Optical Genome Mapping: Unrivaled Structural Variant Detection for Cancer Research and Precision Medicine  
Yannick Delpu, Bionano Genomics, Paris, France

**BREAK**
12:00 PM – 1:00 PM

**Sysmex Inostics**
1:00 PM – 1:20 PM  
Sensitivity matters: How SafeSEQ is optimizing clinical trials through ultra-sensitive and accurate detection of ctDNA  
Hillary Sloane, Sysmex Inostics, Baltimore, Maryland
## September Series

**Sino Biological**  
1:40 PM – 2:00 PM  
**Key Immuno-Oncology Targets**  
Rob Burgess, Sino Biological, Wayne, Pennsylvania

**RareCyte**  
2:00 PM – 2:20 PM  
**Advancing highly multiplexed liquid and tissue biopsy:**  
**Introducing the RareCyte Orion platform**  
Tad George, RareCyte, Seattle, Washington

**Thursday, September 23, 2021**

**Natera**  
10:20 AM - 10:40 AM  
**Detecting molecular residual disease in GI cancers using ctDNA**  
Alexey Aleshin, Natera, Austin, Texas

**NuProbe**  
10:40 AM - 11:00 AM  
**Utilizing rare allele enrichment technology to improve sensitivity of PCR and NGS-based cancer research**  
Nick Gallerani, NuProbe, Houston, TX

**Covaris**  
11:00 AM - 11:20 AM  
**Robust, Reliable, Reproducible Analysis of FFPE Tissues – Ensuring Confidence in Data**  
Kasturi Pal, Covaris, San Diego, California

**Eurofins Discovery**  
11:20 AM – 11:40 PM  
**Oncology Drug Discovery & Early Lifecycle Solutions**  
Alastair King, Eurofins Discovery, St. Charles, Missouri

**ClearLight Biotechnologies**  
11:40 AM – 12:00 PM  
**Enter the Microenvironment: New Opportunities in Tissue Clearing and 3D Imaging**  
Sharla White, ClearLight Biotechnologies, Sunnyvale, California

**BREAK**  
12:00 PM – 1:00 PM

**Partek, Inc.**  
1:00 PM – 1:20 PM  
**How to Easily Perform Compositional Analysis of an Immune Single Cell Dataset - Point, Click, Done**  
Uchenna Emechebe, Partek Inc., St. Louis, Missouri

**Personalis, Inc.**  
1:20 PM – 1:40 PM  
**Advancing Biomarker Discovery: Enabling improved tumor immunogenomics through a comprehensive approach**  
Kedar Hastak, Personalis, Inc., Santa Clara, California